Clinico-genomic analysis reveals KLK2 expression differences in prostate cancer, suggesting its role as a therapeutic target.
This large-scale clinico-genomic analysis reveals distinct KLK2 expression patterns across prostate cancer histologies, tumor sites, and clinical states. These findings provide a molecular framework understanding KLK2 as a therapeutic target in prostate cancer.
No takes yet. Share an insight, caveat, or question.
McKay et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: